Notify me when Knoll Capital Management, LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 33 | $218,013,898 | +$36,434,392 | -$12,236,610 | +$24,197,782 | ALDX, BHVN, NUVB, AVDL, GLD | 13F-HR | 17 Feb 2026, 16:04 |
| Q3 2025 | 38 | $186,187,654 | +$6,154,133 | -$10,170,602 | -$4,016,469 | ALDX, BHVN, GLD, ENTX, MGTX | 13F-HR | 14 Nov 2025, 16:21 |
| Q2 2025 | 38 | $138,451,856 | +$1,761,524 | -$4,107,979 | -$2,346,455 | ALDX, Biohaven Pharmactl Hldg Co L, ENTX, GLD, MGTX | 13F-HR | 14 Aug 2025, 16:00 |
| Q1 2025 | 36 | $153,726,702 | +$14,214,323 | -$12,798,297 | +$1,416,026 | ALDX, Biohaven Pharmactl Hldg Co L, ENTX, GLD, MGTX | 13F-HR | 15 May 2025, 16:01 |
| Q4 2024 | 35 | $155,344,595 | +$6,300,100 | -$1,160,528 | +$5,139,572 | BHVN, ALDX, ENTX, VRNA, ALT | 13F-HR | 14 Feb 2025, 20:12 |
| Q3 2024 | 36 | $206,982,383 | +$13,111,062 | -$76,841,183 | -$63,730,121 | APLT, BHVN, ALDX, AVDL, GLD | 13F-HR | 14 Nov 2024, 16:22 |
| Q2 2024 | 35 | $148,407,303 | +$11,524,328 | $0 | +$11,524,328 | APLT, BHVN, ALDX, AVDL, ALT | 13F-HR | 14 Aug 2024, 16:03 |
| Q1 2024 | 34 | $160,736,263 | +$19,176,390 | -$9,570,296 | +$9,606,094 | APLT, BHVN, ALDX, AVDL, GLD | 13F-HR | 15 May 2024, 16:05 |
| Q4 2023 | 32 | $120,759,584 | +$20,940,036 | -$7,513,200 | +$13,426,836 | BHVN, ALDX, APLT, AVDL, SIL | 13F-HR | 14 Feb 2024, 16:07 |
| Q3 2023 | 37 | $95,604,841 | +$24,991,113 | -$1,240,483 | +$23,750,630 | ALDX, APLT, BHVN, AVDL, HOOK | 13F-HR | 14 Nov 2023, 16:17 |
| Q2 2023 | 26 | $80,706,157 | +$20,989,080 | $0 | +$20,989,080 | ALDX, BHVN, AVDL, HOOK, APLT | 13F-HR | 15 Aug 2023, 07:50 |
| Q1 2023 | 24 | $57,025,930 | +$9,265,051 | -$1,914,806 | +$7,350,245 | ALDX, BHVN, VRNA, GDX, ENTX | 13F-HR | 15 May 2023, 16:25 |
| Q4 2022 | 21 | $43,699,802 | +$12,193,384 | -$16,497,027 | -$4,303,643 | ALDX, BHVN, ALT, GDX, SIL | 13F-HR | 14 Feb 2023, 16:06 |
| Q3 2022 | 33 | $169,877,000 | +$2,630,670 | -$11,573,020 | -$8,942,350 | BHVN, ALDX, ENTX, ALT, Anavex Life Sciences Corp | 13F-HR | 14 Nov 2022, 16:03 |
| Q2 2022 | 41 | $171,172,000 | +$6,037,834 | -$3,029,000 | +$3,008,834 | BHVN, ALDX, EIGR, ENTX, ORGS | 13F-HR | 15 Aug 2022, 17:22 |
| Q1 2022 | 41 | $158,723,000 | +$5,244,562 | -$5,683,266 | -$438,704 | BHVN, ENTX, EIGR, ORGS, ALDX | 13F-HR | 16 May 2022, 16:13 |
| Q4 2021 | 38 | $180,648,000 | +$9,017,992 | -$2,854,930 | +$6,163,062 | BHVN, APLT, ENTX, ORGS, Anavex Life Sciemves Corp | 13F-HR | 14 Feb 2022, 16:04 |
| Q3 2021 | 40 | $200,171,000 | +$912,000 | -$7,939,100 | -$7,027,100 | BHVN, APLT, ENTX, ORGS, CRBP | 13F-HR | 15 Nov 2021, 16:05 |
| Q2 2021 | 42 | $189,909,000 | +$9,468,891 | -$971,333 | +$8,497,558 | BHVN, APLT, ENTX, CRBP, ORGS | 13F-HR | 16 Aug 2021, 16:05 |
| Q1 2021 | 39 | $153,044,000 | +$16,214,290 | -$4,736,427 | +$11,477,863 | BHVN, APLT, CRBP, ORGS, ENTX | 13F-HR | 14 Jun 2021, 13:34 |
| Q4 2020 | 31 | $146,130,000 | +$4,617,473 | $0 | +$4,617,473 | BHVN, APLT, EIGR, CRBP, ORGS | 13F-HR | 16 Feb 2021, 16:08 |
| Q3 2020 | 30 | $121,534,000 | +$6,999,995 | -$1,567,611 | +$5,432,384 | BHVN, APLT, CRBP, ORGS, EIGR | 13F-HR | 16 Nov 2020, 16:08 |
| Q2 2020 | 19 | $173,219,000 | +$8,773,752 | -$2,246,000 | +$6,527,752 | BHVN, CRBP, APLT, ABEO, ORGS | 13F-HR | 14 Aug 2020, 16:11 |
| Q1 2020 | 18 | $106,461,000 | +$7,017,768 | -$6,464,975 | +$552,793 | BHVN, CRBP, APLT, ABEO, BX | 13F-HR | 15 May 2020, 16:01 |
| Q4 2019 | 18 | $135,430,000 | +$8,456,864 | -$10,165,000 | -$1,708,136 | BHVN, CRBP, APLT, ABEO, BX | 13F-HR | 14 Feb 2020, 17:08 |
| Q3 2019 | 23 | $109,262,000 | +$7,697,645 | -$1,656,484 | +$6,041,161 | BHVN, CRBP, BX, ABEO, APLT | 13F-HR | 14 Nov 2019, 16:11 |
| Q2 2019 | 22 | $122,151,000 | +$11,963,110 | -$7,330,688 | +$4,632,422 | CRBP, BHVN, ABEO, BX, KRYS | 13F-HR | 14 Aug 2019, 16:04 |
| Q1 2019 | 17 | $131,596,000 | +$24,793,437 | -$3,829,532 | +$20,963,905 | BHVN, CRBP, ABEO, KRYS, BX | 13F-HR | 15 May 2019, 16:06 |
| Q4 2018 | 15 | $87,900,000 | +$460,000 | -$2,516,739 | -$2,056,739 | BHVN, CRBP, ABEO, KRYS, ALDX | 13F-HR | 14 Feb 2019, 16:59 |
| Q3 2018 | 17 | $118,296,000 | +$5,814,543 | -$5,815,854 | -$1,311 | CRBP, ABEO, BHVN, ALDX, ECOR | 13F-HR | 14 Nov 2018, 16:04 |
| Q2 2018 | 19 | $117,674,000 | +$12,637,289 | $0 | +$12,637,289 | ABEO, BHVN, CRBP, ECOR, AMPE | 13F-HR | 14 Aug 2018, 16:03 |
| Q1 2018 | 13 | $97,391,000 | +$741,000 | -$1,541,793 | -$800,793 | ABEO, CRBP, BHVN, AMPE, KRYS | 13F-HR | 15 May 2018, 16:04 |
| Q4 2017 | 12 | $113,433,000 | +$3,043,105 | -$4,228,550 | -$1,185,445 | ABEO, CRBP, BHVN, AMPE, VBLT | 13F-HR | 14 Feb 2018, 16:26 |
| Q3 2017 | 16 | $116,948,000 | +$3,158,111 | -$508,321 | +$2,649,790 | ABEO, BHVN, CRBP, VBLT, AVXL | 13F-HR | 14 Nov 2017, 16:16 |
| Q2 2017 | 15 | $75,436,000 | +$20,282,000 | -$4,691,295 | +$15,590,705 | CRBP, BHVN, ABEO, AVXL, VBLT | 13F-HR | 14 Aug 2017, 16:28 |
| Q1 2017 | 17 | $66,328,000 | +$13,101,299 | -$3,955,389 | +$9,145,910 | CRBP, ABEO, VBLT, AVXL, NLNK | 13F-HR | 15 May 2017, 16:17 |
| Q4 2016 | 17 | $56,996,000 | +$9,217,619 | -$6,562,289 | +$2,655,330 | CRBP, ABEO, VBLT, AVXL, RTTR | 13F-HR | 14 Feb 2017, 17:07 |
| Q3 2016 | 18 | $57,031,000 | +$869,000 | -$268,603,302 | -$267,734,302 | CRBP, ABEO, SYN, VBLT, CEMP | 13F-HR | 14 Nov 2016, 18:23 |
| Q2 2016 | 22 | $308,530,000 | +$3,967,000 | -$1,430,911 | +$2,536,089 | MDVN, CRBP, SYN, ADHD, AMPE | 13F-HR | 15 Aug 2016, 16:06 |
| Q1 2016 | 22 | $246,277,000 | +$1,638,000 | -$217,008 | +$1,420,992 | MDVN, SYN, AMPE, CRBP, ADHD | 13F-HR | 16 May 2016, 16:09 |
| Q4 2015 | 21 | $269,729,000 | +$7,778,000 | -$1,345,551 | +$6,432,449 | MDVN, AMPE, SYN, ADHD, CEMP | 13F-HR | 17 Feb 2016, 14:29 |
| Q3 2015 | 19 | $235,563,000 | +$95,783,436 | -$40,047 | +$95,743,389 | MDVN, AMPE, SYN, ADHD, ABEO | 13F-HR | 16 Nov 2015, 16:14 |
| Q2 2015 | 19 | $310,193,000 | +$14,149,521 | -$695,581 | +$13,453,940 | MDVN, SYN, AMPE, ADHD, ABEO | 13F-HR | 14 Aug 2015, 16:23 |
| Q1 2015 | 17 | $343,460,000 | +$7,970,120 | -$7,890,582 | +$79,538 | MDVN, AMPE, SYN, ADHD, NLNK | 13F-HR | 15 May 2015, 16:10 |
| Q4 2014 | 14 | $254,119,000 | +$4,754,694 | -$1,180,023 | +$3,574,671 | MDVN, AMPE, SYN, ADHD, NLNK | 13F-HR | 17 Feb 2015, 16:05 |
| Q3 2014 | 1 | $2,458,000 | $0 | $0 | $0 | ORPN | New Holdings | 09 Dec 2014, 10:35 |
| Q3 2014 | 15 | $257,075,000 | +$3,937,836 | -$4,270,409 | -$332,573 | MDVN, AMPE, ADHD, KERX, ORPN | 13F-HR | 14 Nov 2014, 16:11 |
| Q2 2014 | 15 | $224,399,000 | +$1,281,000 | -$2,461,857 | -$1,180,857 | MDVN, AMPE, ADHD, KERX, SYN | 13F-HR | 14 Aug 2014, 16:16 |
| Q1 2014 | 16 | $193,229,000 | +$9,142,689 | -$16,009,482 | -$6,866,793 | MDVN, AMPE, ADHD, SYN, KERX | 13F-HR | 15 May 2014, 16:41 |
| Q4 2013 | 13 | $197,526,000 | $0 | $0 | $0 | MDVN, AMPE, ADHD, KERX, SQNM | 13F-HR | 14 Feb 2014, 16:13 |